Identification of 1-({[1-(4-fluorophenyl)-5-(2-methoxyphenyl)-1H-pyrazol-3- yl]carbonyl}amino)cyclohexane carboxylic acid as a selective nonpeptide neurotensin receptor type 2 compound

Journal of Medicinal Chemistry

Volumn 57, Issue 12, 2014, Pages 5318-5332

  Thomas, James B ^a   Giddings, Angela M ^a   Wiethe, Robert W ^a   Olepu, Srinivas ^a   Warner, Keith R ^a   Sarret, Philippe ^b   Gendron, Louis ^b   Longpre, Jean Michel ^b   Zhang, Yanan ^a   Runyon, Scott P ^a   Gilmour, Brian P ^a  

^a RTI INTERNATIONAL   (United States)

^b UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 [[[1 (4 FLUOROPHENYL) 5 (2 METHOXYPHENYL) 1H PYRAZOL 3 YL]CARBONYL]AMINO]CYCLOHEXANE CARBOXYLIC ACID; NEUROTENSIN RECEPTOR; NEUROTENSIN RECEPTOR 2; NEUROTENSIN RECEPTOR ANTAGONIST; NTRC 739; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CALCIUM MOBILIZATION ASSAY; CHO CELL LINE; DRUG IDENTIFICATION; DRUG STRUCTURE; NONHUMAN; PROTEIN EXPRESSION;

ANALGESICS; ANIMALS; CALCIUM; CHO CELLS; CRICETULUS; CYCLOHEXANECARBOXYLIC ACIDS; DRUG PARTIAL AGONISM; PYRAZOLES; RADIOLIGAND ASSAY; RATS; RECEPTORS, NEUROTENSIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84903553455     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5003843     Document Type: Article

References (63)

1. Caraway, R.; Leeman, S. E. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami J. Biol. Chem. 1973, 248, 6854-6861
2. Boules, M.; Li, Z.; Smith, K.; Fredrickson, P.; Richelson, E. Diverse roles of neurotensin agonists in the central nervous system Front. Endocrinol. 2013, 4, 1-16
3. Hokfelt, T.; Everitt, B. J.; Theodorsson-Norheim, E.; Goldstein, M. Occurrence of neurotensinlike immunoreactivity in subpopulations of hypothalamic, mesencephalic, and medullary catecholamine neurons J. Comp. Neurol. 1984, 222, 543-559
4. Kalivas, P. W.; Miller, J. S. Neurotensin neurons in the ventral tegmental area project to the medial nucleus accumbens Brain. Res. 1984, 300, 157-160
5. Kalivas, P. W.; Nemeroff, C. B.; Prange, A. J., Jr. Neuroanatomical site specific modulation of spontaneous motor activity by neurotensin Eur. J. Pharmacol. 1982, 78, 471-474
6. Ford, A. P.; Marsden, C. A. In vivo neurochemical and behavioural effects of intracerebrally administered neurotensin and d -Trp11-neurotensin on mesolimbic and nigrostriatal dopaminergic function in the rat Brain Res. 1990, 534, 243-250
7. Nemeroff, C. B.; Hernandez, D. E.; Luttinger, D.; Kalivas, P. W.; Prange, A. J., Jr. Interactions of neurotensin with brain dopamine systems Ann. N. Y. Acad. Sci. 1982, 400, 330-344
8. Clineschmidt, B. V.; McGuffin, J. C. Neurotensin administered intracisternally inhibits responsiveness of mice to noxious stimuli Eur. J. Pharmacol. 1977, 46, 395-396
9. Nemeroff, C. B.; Osbahr, A. J., III; Manberg, P. J.; Ervin, G. N.; Prange, A. J., Jr. Alterations in nociception and body temperature after intracisternal administration of neurotensin, beta-endorphin, other endogenous peptides, and morphine Proc. Natl. Acad. Sci. U. S. A. 1979, 76, 5368-5371
10. Tanaka, K.; Masu, M.; Nakanishi, S. Structure and functional expression of the cloned rat neurotensin receptor Neuron 1990, 4, 847-854
11. Vita, N.; Laurent, P.; Lefort, S.; Chalon, P.; Dumont, X.; Kaghad, M.; Gully, D.; Le Fur, G.; Ferrara, P.; Caput, D. Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor FEBS Lett. 1993, 317, 139-142
12. Chalon, P.; Vita, N.; Kaghad, M.; Guillemot, M.; Bonnin, J.; Delpech, B.; Le Fur, G.; Ferrara, P.; Caput, D. Molecular cloning of a levocabastine- sensitive neurotensin binding site FEBS Lett. 1996, 386, 91-94
13. Mazella, J.; Botto, J. M.; Guillemare, E.; Coppola, T.; Sarret, P.; Vincent, J. P. Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain J. Neurosci. 1996, 16, 5613-5620
14. Mazella, J.; Zsurger, N.; Navarro, V.; Chabry, J.; Kaghad, M.; Caput, D.; Ferrara, P.; Vita, N.; Gully, D.; Maffrand, J. P.; Vincent, J. P. The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor J. Biol. Chem. 1998, 273, 26273-26276
15. Nemeroff, C. B. Neurotensin: perchance an endogenous neuroleptic? Biol. Psychiatry 1980, 15, 283-302
16. Kitabgi, P. Targeting neurotensin receptors with agonists and antagonists for therapeutic purposes Curr. Opin. Drug Discovery Dev. 2002, 5, 764-776
17. Boules, M.; Fredrickson, P.; Richelson, E. Neurotensin agonists as an alternative to antipsychotics Expert Opin. Invest. Drugs 2005, 14, 359-369
18. Tatetsu, S.; Takaki, M.; Miyagawa, T.; Kozuma, Y.; Kozuma, Y. A study on the experimental production in the brain of histopathological changes resembling schizophrenia by chronic methamphetamine administration Seishin Shinkeigaku Zasshi 1967, 69, 1363-1370
19. Machiyama, Y. Chronic methamphetamine intoxication model of schizophrenia in animals Schizophrenia Bull. 1992, 18, 107-113
20. Frankel, P. S.; Hoonakker, A. J.; Alburges, M. E.; McDougall, J. W.; McFadden, L. M.; Fleckenstein, A. E.; Hanson, G. R. Effect of methamphetamine self-administration on neurotensin systems of the basal ganglia J. Pharmacol. Exp. Ther. 2011, 336, 809-815
21. Hanson, G. R.; Hoonakker, A. J.; Robson, C. M.; McFadden, L. M.; Frankel, P. S.; Alburges, M. E. Response of neurotensin basal ganglia systems during extinction of methamphetamine self-administration in rat J. Pharmacol. Exp. Ther. 2013, 346, 173-181
22. Dobner, P. R. Neurotensin and pain modulation Peptides 2006, 27, 2405-2414
23. Boules, M.; Johnston, H.; Tozy, J.; Smith, K.; Li, Z.; Richelson, E. Analgesic synergy of neurotensin receptor subtype 2 agonist NT79 and morphine Behav. Pharmacol. 2011, 22, 573-581
24. Bredeloux, P.; Cavelier, F.; Dubuc, I.; Vivet, B.; Costentin, J.; Martinez, J. Synthesis and biological effects of c(Lys-Lys-Pro-Tyr-Ile-Leu-Lys- Lys-Pro-Tyr-Ile-Leu) (JMV2012), a new analogue of neurotensin that crosses the blood-brain barrier J. Med. Chem. 2008, 51, 1610-1616
25. Bredeloux, P.; Costentin, J.; Dubuc, I. Interactions between NTS2 neurotensin and opioid receptors on two nociceptive responses assessed on the hot plate test in mice Behav. Brain Res. 2006, 175, 399-407
26. Smith, K. E.; Boules, M.; Williams, K.; Richelson, E. NTS1 and NTS2 mediate analgesia following neurotensin analog treatment in a mouse model for visceral pain Behav. Brain Res. 2012, 232, 93-97
27. Hughes, F. M.; Shaner, B. E.; May, L. A.; Zotian, L.; Brower, J. O.; Woods, R. J.; Cash, M.; Morrow, D.; Massa, F.; Mazella, J.; Dix, T. A. Identification and functional characterization of a stable, centrally active derivative of the neurotensin (8-13) fragment as a potential first-in-class analgesic J. Med. Chem. 2010, 53, 4623-4632
28. Sarret, P.; Esdaile, M. J.; Perron, A.; Martinez, J.; Stroh, T.; Beaudet, A. Potent spinal analgesia elicited through stimulation of NTS2 neurotensin receptors J. Neurosci. 2005, 25, 8188-8196
29. Tetreault, P.; Beaudet, N.; Perron, A.; Belleville, K.; Rene, A.; Cavelier, F.; Martinez, J.; Stroh, T.; Jacobi, A. M.; Rose, S. D.; Behlke, M. A.; Sarret, P. Spinal NTS2 receptor activation reverses signs of neuropathic pain FASEB J. 2013, 27
30. Finnerup, N. B.; Sindrup, S. H.; Jensen, T. S. The evidence for pharmacological treatment of neuropathic pain Pain 2010, 150, 573-581
31. Carraway, R. L.; S, E. Structural requirements for the biological activity of neurotensin, a new vasoactive peptide. In Peptides: Chemistry, Structure and Biology; Walter, R.; Meienhofer, J., Eds.; Ann Arbor Science: Ann Arbor, MI, 1975; pp 679-685.
32. Dubuc, I.; Sarret, P.; Labbe-Jullie, C.; Botto, J. M.; Honore, E.; Bourdel, E.; Martinez, J.; Costentin, J.; Vincent, J. P.; Kitabgi, P.; Mazella, J. Identification of the receptor subtype involved in the analgesic effect of neurotensin J. Neurosci. 1999, 19, 503-510
33. Doulut, S.; Rodriguez, M.; Lugrin, D.; Vecchini, F.; Kitabgi, P.; Aumelas, A.; Martinez, J. Reduced peptide bond pseudopeptide analogues of neurotensin Pept. Res. 1992, 5, 30-38
34. Boules, M.; Liang, Y.; Briody, S.; Miura, T.; Fauq, I.; Oliveros, A.; Wilson, M.; Khaniyev, S.; Williams, K.; Li, Z.; Qi, Y.; Katovich, M.; Richelson, E. NT79: A novel neurotensin analog with selective behavioral effects Brain Res. 2010, 1308, 35-46
35. Einsiedel, J.; Held, C.; Hervet, M.; Plomer, M.; Tschammer, N.; Hubner, H.; Gmeiner, P. Discovery of highly potent and neurotensin receptor 2 selective neurotensin mimetics J. Med. Chem. 2011, 54, 2915-2923
36. Held, C.; Plomer, M.; Hubner, H.; Meltretter, J.; Pischetsrieder, M.; Gmeiner, P. Development of a metabolically stable neurotensin receptor 2 (NTS2) ligand ChemMedChem 2013, 8, 75-81
37. Gully, D.; Canton, M.; Boigegrain, R.; Jeanjean, F.; Molimard, J. C.; Poncelet, M.; Gueudet, C.; Heaulme, M.; Leyris, R.; Brouard, A. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor Proc. Natl. Acad. Sci. U. S. A. 1993, 90, 65-69
38. Gully, D.; Labeeuw, B.; Boigegrain, R.; Oury-Donat, F.; Bachy, A.; Poncelet, M.; Steinberg, R.; Suaud-Chagny, M. F.; Santucci, V.; Vita, N.; Pecceu, F.; Labbe-Jullie, C.; Kitabgi, P.; Soubrie, P.; Le Fur, G.; Maffrand, J. P. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist J. Pharmacol. Exp. Ther. 1997, 280, 802-812
39. Dahl, R.; Pedersen, B.; Larsen, B. Intranasal levocabastine for the treatment of seasonal allergic rhinitis: a multicentre, double-blind, placebo-controlled trial Rhinology 1995, 33, 121-125
40. Gendron, L.; Perron, A.; Payet, M. D.; Gallo-Payet, N.; Sarret, P.; Beaudet, A. Low-affinity neurotensin receptor (NTS2) signaling: internalization-dependent activation of extracellular signal-regulated kinases 1/2 Mol. Pharmacol. 2004, 66, 1421-1430
41. Labeeuw, B.; Gully, D.; Jeanjean, F.; Molimard, J.; Boigegrain, R. Substituted 1-Phenyl-3-pyrazolecarboxamides Active on the Neurotensin Receptors Their Preparation and Pharmaceutical Compositions Containing Them. U.S. Patent 5,723,483, 1998.
42. Jiang, J.; Huang, W.; Zhai, J.; Liu, H.; Cai, Q.; Xu, L.; Wang, W.; Ji, Y. 'One-pot' synthesis of 4-substituted 1,5-diaryl-1 H -pyrazole-3-carboxylates via lithium tert -butoxide-mediated sterically hindered Claisen condensation and Knorr reaction Tetrahedron 2013, 69, 627-635
43. Baxendale, I. R.; Cheung, S.; Kitching, M. O.; Ley, S. V.; Shearman, J. W. The synthesis of neurotensin antagonist SR 48692 for prostate cancer research Biorg. Med. Chem. 2013, 21, 4378-4387
44. Lindh, J.; Sojberg, P. J. R.; M, L. Synthesis of aryl ketones by palladium(II)-catalyzed decarboxylative addition of benzoic acids to nitriles Angew. Chem. Int. Ed. 2010, 49, 7733-7737
45. Quéré, L. Etude de l'interaction ligand-récepteur neurotensinergique. Ph.D. Thesis. University of Namur, Namur, Belgium, 1995.
46. Nagasawa, H. T.; Eberling, J. A.; Shirota, F. N. 2-Aminoadamantane-2- carboxylic acid, a rigid, achiral, tricyclic alpha-amino acid with transport inhibitory properties J. Med. Chem. 1973, 16, 823-826
47. Yamada, M.; Yamada, M.; Lombet, A.; Forgez, P.; Rostene, W. Distinct functional characteristics of levocabastine sensitive rat neurotensin NT2 receptor expressed in Chinese hamster ovary cells Life Sci. 1998, 62, 375-380
48. Richard, F.; Barroso, S.; Martinez, J.; Labbe-Jullie, C.; Kitabgi, P. Agonism, inverse agonism, and neutral antagonism at the constitutively active human neurotensin receptor 2 Mol. Pharmacol. 2001, 60, 1392-1398
49. Vita, N.; Oury-Donat, F.; Chalon, P.; Guillemot, M.; Kaghad, M.; Bachy, A.; Thurneyssen, O.; Garcia, S.; Poinot-Chazel, C.; Casellas, P.; Keane, P.; Le Fur, G.; Maffrand, J. P.; Soubrie, P.; Caput, D.; Ferrara, P. Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells Eur. J. Pharmacol. 1998, 360, 265-272
50. Holst, B.; Holliday, N. D.; Bach, A.; Elling, C. E.; Cox, H. M.; Schwartz, T. W. Common structural basis for constitutive activity of the ghrelin receptor family J. Biol. Chem. 2004, 279, 53806-53817
51. Gaddum, J. H. Theories of drug antagonism Pharmacol. Rev. 1957, 9, 211-218
52. Kenakin, T.; Jenkinson, S.; Watson, C. Determining the potency and molecular mechanism of action of insurmountable antagonists J. Pharmacol. Exp. Ther. 2006, 319, 710-723
53. Roussy, G.; Dansereau, M. A.; Baudisson, S.; Ezzoubaa, F.; Belleville, K.; Beaudet, N.; Martinez, J.; Richelson, E.; Sarret, P. Evidence for a role of NTS2 receptors in the modulation of tonic pain sensitivity Mol. Pain 2009, 5, 38
54. Smith, D. J.; Hawranko, A. A.; Monroe, P. J.; Gully, D.; Urban, M. O.; Craig, C. R.; Smith, J. P.; Smith, D. L. Dose-dependent pain-facilitatory and -inhibitory actions of neurotensin are revealed by SR 48692, a nonpeptide neurotensin antagonist: influence on the antinociceptive effect of morphine J. Pharmacol. Exp. Ther. 1997, 282, 899-908
55. Costa, F. G.; Frussa-Filho, R.; Felicio, L. F. The neurotensin receptor antagonist, SR48692, attenuates the expression of amphetamine-induced behavioural sensitisation in mice Eur. J. Pharmacol. 2001, 428, 97-103
56. Gully, D.; Lespy, L.; Canton, M.; Rostene, W.; Kitabgi, P.; Le Fur, G.; Maffrand, J. P. Effect of the neurotensin receptor antagonist SR48692 on rat blood pressure modulation by neurotensin Life Sci. 1996, 58, 665-674
57. Labbe-Jullie, C.; Barroso, S.; Nicolas-Eteve, D.; Reversat, J. L.; Botto, J. M.; Mazella, J.; Bernassau, J. M.; Kitabgi, P. Mutagenesis and modeling of the neurotensin receptor NTR1. Identification of residues that are critical for binding SR 48692, a nonpeptide neurotensin antagonist J. Biol. Chem. 1998, 273, 16351-16357
58. Labbe-Jullie, C.; Botto, J. M.; Mas, M. V.; Chabry, J.; Mazella, J.; Vincent, J. P.; Gully, D.; Maffrand, J. P.; Kitabgi, P. [3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor Mol. Pharmacol. 1995, 47, 1050-1056
59. Henry, J. A.; Horwell, D. C.; Meecham, K. G.; Rees, D. C. A structure-affinity study of the amino acid side-chains in neurotensin: N and C terminal deletions and Ala-scan Bioorg. Med. Chem. Lett. 1993, 3, 949-952
60. Quéré, L.; Boigegrain, R.; Jeanjean, F.; Gully, D.; Evrard, G.; Durant, F. Structural requirements of non-peptide neurotensin receptor antagonists J. Chem. Soc., Perkin Trans. 1996, 2, 2639-2646
61. Labbe-Jullie, C.; Deschaintres, S.; Gully, D.; Le Fur, G.; Kitabgi, P. Effect of the nonpeptide neurotensin antagonist, SR 48692, and two enantiomeric analogs, SR 48527 and SR 49711, on neurotensin binding and contractile responses in guinea pig ileum and colon J. Pharmacol. Exp. Ther. 1994, 271, 267-276
62. Labeeuw, B.; Gully, D.; Jeanjean, F.; Molimard, J.; Boigegrain, R. Substituted 1-naphthyl-3-pyrazolecarboxamides which are active on neurotensin, their preparation and pharmaceutical compositions containing them. US005502059, 1996.
63. Thomas, J. B.; Navarro, H.; Warner, K. R.; Gilmour, B. The identification of nonpeptide neurotensin receptor partial agonists from the potent antagonist SR48692 using a calcium mobilization assay Bioorg. Med. Chem. Lett. 2009, 19, 1438-1441